Neumora Therapeutics Inc. has announced positive results from its Phase 1b signal-seeking study of NMRA-511, a selective vasopressin 1a receptor antagonist, in patients with agitation associated with Alzheimer’s disease. The study demonstrated a clinically meaningful reduction of 15.7 points on the mean Cohen-Mansfield Agitation Inventory (CMAI) total score and showed a favorable safety and tolerability profile, with treatment-emergent adverse events mostly mild to moderate and a low discontinuation rate. The company plans to advance NMRA-511 development by initiating a multiple ascending dose extension study and formulation development for once-daily extended-release dosing in 2026, as well as a Phase 2/3 dose-ranging study. These findings were presented during a company webcast and conference call held on January 5, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neumora Therapeutics Inc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9619496-en) on January 05, 2026, and is solely responsible for the information contained therein.